TW202345837A - 呼吸道刺激劑鼻用調配物 - Google Patents

呼吸道刺激劑鼻用調配物 Download PDF

Info

Publication number
TW202345837A
TW202345837A TW112112709A TW112112709A TW202345837A TW 202345837 A TW202345837 A TW 202345837A TW 112112709 A TW112112709 A TW 112112709A TW 112112709 A TW112112709 A TW 112112709A TW 202345837 A TW202345837 A TW 202345837A
Authority
TW
Taiwan
Prior art keywords
substituted
acid
rrt
nasal formulation
formulation
Prior art date
Application number
TW112112709A
Other languages
English (en)
Chinese (zh)
Inventor
法蘭克 黛安娜
喬瑟夫 V 伯格利兹
Original Assignee
美商安納萊爾治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商安納萊爾治療公司 filed Critical 美商安納萊爾治療公司
Publication of TW202345837A publication Critical patent/TW202345837A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW112112709A 2022-04-01 2023-03-31 呼吸道刺激劑鼻用調配物 TW202345837A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263326578P 2022-04-01 2022-04-01
US63/326,578 2022-04-01

Publications (1)

Publication Number Publication Date
TW202345837A true TW202345837A (zh) 2023-12-01

Family

ID=88195037

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112112709A TW202345837A (zh) 2022-04-01 2023-03-31 呼吸道刺激劑鼻用調配物

Country Status (10)

Country Link
US (1) US20230310440A1 (https=)
EP (1) EP4504206A4 (https=)
JP (1) JP2025511227A (https=)
KR (1) KR20240167901A (https=)
CN (1) CN119630402A (https=)
AU (1) AU2023241731A1 (https=)
CA (1) CA3247210A1 (https=)
MX (1) MX2024012104A (https=)
TW (1) TW202345837A (https=)
WO (1) WO2023192602A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025511227A (ja) * 2022-04-01 2025-04-15 エナラーレ セラピューティクス インコーポレイテッド 呼吸器刺激性経鼻製剤
US20230414624A1 (en) * 2022-06-24 2023-12-28 Enalare Therapeutics Inc. Methods of treating neurological ventilatory insufficiency
KR102882277B1 (ko) 2023-11-22 2025-11-06 헤일러코리아 주식회사 구분된 공간을 구비하는 교체형 카트리지 및 이를 포함하는 네블라이징 디바이스
KR102908992B1 (ko) 2023-11-22 2026-01-14 박세진 네블라이징 디바이스용 교체형 카트리지

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US20050053659A1 (en) * 2003-09-10 2005-03-10 Pace Gary W. Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness
US20120295911A1 (en) * 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
AU2011336764B2 (en) * 2010-11-29 2017-02-23 Galleon Pharmaceuticals, Inc. Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
WO2012138797A1 (en) * 2011-04-05 2012-10-11 Amira Pharmaceuticals, Inc. 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders
SG11201407964YA (en) * 2012-05-29 2014-12-30 Galleon Pharmaceuticals Inc Novel compounds and compositions for treatment of breathing control disorders or diseases
US11903951B2 (en) * 2016-06-03 2024-02-20 M et P Pharma AG Nasal pharmaceutical compositions with a porous excipient
WO2019182745A1 (en) * 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
CA3141612A1 (en) * 2019-05-22 2020-11-26 Enalare Therapeutics Inc. Methods and pharmaceutical compositions to treat drug overdose
CA3236586A1 (en) * 2021-11-02 2023-05-11 Joseph Pergolizzi Methods of treating respiratory depression modulated by a non-opioid agent
JP2025511227A (ja) * 2022-04-01 2025-04-15 エナラーレ セラピューティクス インコーポレイテッド 呼吸器刺激性経鼻製剤

Also Published As

Publication number Publication date
WO2023192602A3 (en) 2024-01-18
CA3247210A1 (en) 2023-10-05
AU2023241731A1 (en) 2024-10-31
JP2025511227A (ja) 2025-04-15
WO2023192602A2 (en) 2023-10-05
US20230310440A1 (en) 2023-10-05
EP4504206A2 (en) 2025-02-12
KR20240167901A (ko) 2024-11-28
MX2024012104A (es) 2025-01-09
EP4504206A4 (en) 2026-03-25
CN119630402A (zh) 2025-03-14

Similar Documents

Publication Publication Date Title
TW202345837A (zh) 呼吸道刺激劑鼻用調配物
US12150461B2 (en) Nicotinamide adenine dinucleotide (NAD) compositions, methods of manufacturing thereof, and methods of use thereof
EP3284506B1 (en) Soluble microneedle containing ingredient for controlling release of neurotransmitters
US20250114370A1 (en) Methods and compositions for treating drug overdose
US20250032496A1 (en) Methods of treating respiratory depression modulated by a non-opioid agent
WO2020004194A1 (ja) 外用組成物
TW202333732A (zh) 呼吸道刺激劑之非經腸調配物
US20240238303A1 (en) Large-conductance potassium channel modulators, compositions thereof, methods of manufacturing thereof, and methods of use thereof
UA122923C2 (uk) Препарат для шкіри місцевого застосування проти зморщок
TW202529771A (zh) 用於治療藥物過量的方法及組合物
US20230414624A1 (en) Methods of treating neurological ventilatory insufficiency
CN118829433A (zh) 呼吸刺激剂肠胃外制剂
JP2017081825A (ja) メラニン産生抑制剤